Extracellular signal-regulated protein kinase, but not c-Jun N-terminal kinase, is activated by type II gonadotropin-releasing hormone involved in the inhibition of ovarian cancer cell proliferation.

Although a novel second form of GnRH (GnRH-II) has been reported to have an antiproliferative effect on gynecologic cancer cells, its biological mechanism remains to be elucidated. We have previously demonstrated that GnRH-II activates p38 MAPK. There is accumulating evidence that activation of MAPKs by GnRH-I and -II is important for cell proliferation, differentiation, and apoptosis. In the present study, we further investigated the involvement of GnRH-II in the inhibition of cell proliferation and activation of ERK1/2 and c-Jun N-terminal protein kinase/stress-activated protein kinase (JNK/SAPK) in ovarian cancer cells, OVCAR-3. The [(3)H]thymidine incorporation and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays revealed that treatment with GnRH-II suppresses cell proliferation of ovarian cancer cells. Western blot analysis demonstrated that ERK1/2 was activated by GnRH-II (100 nm). Moreover, PD98059 (10 mum), an inhibitor of a MAPK/ERK kinase, reversed the activation of ERK1/2 induced by GnRH-II. The activation of ERK1/2 by GnRH-II subsequently phosphorylated Elk-1 as a downstream pathway, which was blocked by PD98059. On the other hand, it is not likely that GnRH-II activates the JNK/SAPK pathway. Taken together, these results indicate that the ERK1/2 pathway is involved in the effect of GnRH-II on antiproliferation and may be an important target for ovarian cancer therapy.

[1]  L. Luttrell,et al.  Activation of extracellular signal-regulated kinase in human prostate cancer. , 1999, The Journal of urology.

[2]  T. Susini,et al.  GnRH analogs in gynecological oncology: a review. , 1992, Journal of chemotherapy.

[3]  P. Leung,et al.  Reproductive Biology and Endocrinology Open Access Mitogen-activated Protein Kinases in Normal and (pre)neoplastic Ovarian Surface Epithelium , 2022 .

[4]  C. Redmond,et al.  Endocrine treatment of breast cancer in women. , 1990, Endocrine reviews.

[5]  Huitu Liu,et al.  MAPK signal pathways in the regulation of cell proliferation in mammalian cells , 2002, Cell Research.

[6]  A. Schally Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis☆ , 1999, Peptides.

[7]  H. Krishnamurthy,et al.  Activation of extracellular-regulated kinase pathways in ovarian granulosa cells by the novel growth factor type 1 follicle-stimulating hormone receptor. Role in hormone signaling and cell proliferation. , 2000, The Journal of biological chemistry.

[8]  R. Seger,et al.  Stimulation of Jun N-terminal kinase (JNK) by gonadotropin-releasing hormone in pituitary alpha T3-1 cell line is mediated by protein kinase C, c-Src, and CDC42. , 1998, Molecular endocrinology.

[9]  C. Slaughter,et al.  ERK phosphorylation potentiates Elk‐1‐mediated ternary complex formation and transactivation. , 1995, The EMBO journal.

[10]  N. Kennedy,et al.  Role of JNK in Tumor Development , 2003, Cell cycle.

[11]  N. Auersperg,et al.  Estradiol regulates gonadotropin-releasing hormone (GnRH) and its receptor gene expression and antagonizes the growth inhibitory effects of GnRH in human ovarian surface epithelial and ovarian cancer cells. , 2001, Endocrinology.

[12]  C. Eddy,et al.  Action of Gonadotropin-Releasing Hormone II on the Baboon Ovary1 , 2003, Biology of reproduction.

[13]  A. Clerk,et al.  Regulation of the ERK subgroup of MAP kinase cascades through G protein-coupled receptors. , 1997, Cellular signalling.

[14]  A. Lin Activation of the JNK signaling pathway: Breaking the brake on apoptosis , 2003, BioEssays : news and reviews in molecular, cellular and developmental biology.

[15]  Adam J Pawson,et al.  A novel mammalian receptor for the evolutionarily conserved type II GnRH , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[16]  A. Schally,et al.  Hypothalamic Hormones and Cancer , 2001, Frontiers in Neuroendocrinology.

[17]  J. Zidan,et al.  Treating relapsed epithelial ovarian cancer with luteinizing hormone-releasing agonist (goserelin) after failure of chemotherapy. , 2002, The Israel Medical Association journal : IMAJ.

[18]  P. Cohen,et al.  Specificity and mechanism of action of some commonly used protein kinase inhibitors. , 2000, The Biochemical journal.

[19]  P. Leung,et al.  Follicle-stimulating hormone activates mitogen-activated protein kinase in preneoplastic and neoplastic ovarian surface epithelial cells. , 2002, The Journal of clinical endocrinology and metabolism.

[20]  J. Sussenbach,et al.  The role of MAP kinase in TPA-mediated cell cycle arrest of human breast cancer cells , 1998, Oncogene.

[21]  K. Smalley,et al.  A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? , 2003, International journal of cancer.

[22]  G. Emons,et al.  Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. , 2002, The Journal of clinical endocrinology and metabolism.

[23]  I. Herskowitz MAP kinase pathways in yeast: For mating and more , 1995, Cell.

[24]  R. Seger,et al.  Extracellular Signal-Regulated Kinase and c-Src, But Not Jun N-Terminal Kinase, Are Involved in Basal and Gonadotropin-Releasing Hormone-Stimulated Activity of the Glycoprotein Hormone α-Subunit Promoter , 2003 .

[25]  A. Yen,et al.  Retinoic acid induced mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase-dependent MAP kinase activation needed to elicit HL-60 cell differentiation and growth arrest. , 1998, Cancer research.

[26]  N. Auersperg,et al.  The regulation of apoptosis by activin and transforming growth factor-beta in early neoplastic and tumorigenic ovarian surface epithelium. , 2001, The Journal of clinical endocrinology and metabolism.

[27]  G. Emons,et al.  Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer , 2003, Reproductive biology and endocrinology : RB&E.

[28]  E. Goldsmith,et al.  How MAP Kinases Are Regulated (*) , 1995, The Journal of Biological Chemistry.

[29]  M. Cobb,et al.  Mitogen-activated protein kinase pathways. , 1997, Current opinion in cell biology.

[30]  N. Auersperg,et al.  Expression and antiproliferative effect of a second form of gonadotropin-releasing hormone in normal and neoplastic ovarian surface epithelial cells. , 2001, The Journal of clinical endocrinology and metabolism.

[31]  P. Leung,et al.  Differential expression of activin/inhibin subunit and activin receptor mRNAs in normal and neoplastic ovarian surface epithelium (OSE) , 2001, Molecular and Cellular Endocrinology.

[32]  J. Hayakawa,et al.  Role of mitogen-activated protein kinase/extracellular signal-regulated kinase cascade in gonadotropin-releasing hormone-induced growth inhibition of a human ovarian cancer cell line. , 1999, Cancer research.

[33]  P. Leung,et al.  Gonadotropin-releasing hormone activates mitogen-activated protein kinase in human ovarian and placental cells , 2000, Molecular and Cellular Endocrinology.

[34]  A. Nordheim,et al.  Activation of ternary complex factor Elk‐1 by MAP kinases. , 1993, The EMBO journal.

[35]  P. Leung,et al.  Autocrine role of gonadotropin-releasing hormone and its receptor in ovarian cancer cell growth , 2007, Endocrine.

[36]  N. Ahn,et al.  Signal transduction through MAP kinase cascades. , 1998, Advances in cancer research.

[37]  S. Krawetz,et al.  Type II Gonadotropin-Releasing Hormone Receptor Transcripts in Human Sperm1 , 2002, Biology of reproduction.

[38]  H. Hanafusa,et al.  v-Crk activates the phosphoinositide 3-kinase/AKT pathway in transformation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Adam J Pawson,et al.  Gonadotropin-releasing hormone receptors. , 2004, Endocrine reviews.

[40]  A. Giordano,et al.  GnRH and steroids in cancer. , 2002, Frontiers in bioscience : a journal and virtual library.

[41]  K. Reddy,et al.  Mitogen‐activated protein kinase (MAPK) regulates the expression of progelatinase B (MMP‐9) in breast epithelial cells , 1999, International journal of cancer.

[42]  J. D. Neill GnRH and GnRH receptor genes in the human genome. , 2002, Endocrinology.

[43]  A. Campana,et al.  Comparison of the effects of GnRH-I and GnRH-II on HCG synthesis and secretion by first trimester trophoblast. , 2001, Molecular human reproduction.

[44]  P. Leung,et al.  Type II gonadotropin-releasing hormone stimulates p38 mitogen-activated protein kinase and apoptosis in ovarian cancer cells. , 2004, The Journal of clinical endocrinology and metabolism.

[45]  D. Mcfadden,et al.  COX-2 inhibition demonstrates potent anti-proliferative effects on bladder cancer in vitro. , 2003, The Journal of surgical research.

[46]  M. Jung,et al.  Role of ATM in Oxidative Stress-mediated c-Jun Phosphorylation in Response to Ionizing Radiation and CdCl2 * , 2001, The Journal of Biological Chemistry.

[47]  G L Johnson,et al.  Organization and regulation of mitogen-activated protein kinase signaling pathways. , 1999, Current opinion in cell biology.

[48]  L. Kiesel,et al.  Clinical use of GnRH analogues , 2002, Clinical endocrinology.

[49]  K. Miyazawa,et al.  High Intensity ERK Signal Mediates Hepatocyte Growth Factor-induced Proliferation Inhibition of the Human Hepatocellular Carcinoma Cell Line HepG2* , 2001, The Journal of Biological Chemistry.

[50]  J. D. Neill Minireview: GnRH and GnRH Receptor Genes in the Human Genome. , 2002, Endocrinology.

[51]  P. Wang,et al.  Five-transmembrane domains appear sufficient for a G protein-coupled receptor: functional five-transmembrane domain chemokine receptors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[52]  N. Ahn,et al.  Transformation of mammalian cells by constitutively active MAP kinase kinase. , 1994, Science.

[53]  N. Auersperg,et al.  Estradiol up-regulates antiapoptotic Bcl-2 messenger ribonucleic acid and protein in tumorigenic ovarian surface epithelium cells. , 2001, Endocrinology.